MDT · Medtronic plc
Market Cap
$115.17B
Shares
1.28B
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$36.36B
+8.4%
FY2026
Net Income
$4.8B
+3%
FY2026
Gross Margin
69.77%
+1pp
FY2018
Operating Margin
17.78%
0pp
FY2026
Diluted EPS
$3.73
+3.3%
FY2026
Operating Cash Flow
$7.33B
+4.1%
FY2026
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | $36.36B | $33.54B | $32.36B | $31.23B | $31.69B | $30.12B | $28.91B | $30.56B | $29.95B | $29.71B | $28.83B | $20.26B | $17.01B | $16.59B | |
| — | $383M | $511M | $597M | $386M | $186M | — | — | — | — | — | — | — | — | — | |
| — | $12.72B | $11.63B | $11.22B | $10.72B | $10.15B | $10.48B | $9.42B | $9.16B | $9.07B | $9.29B | $9.14B | $6.31B | $4.33B | $4.13B | |
| $19.49B | — | — | — | — | — | — | — | — | $20.9B | $20.42B | $19.69B | $13.95B | $12.67B | — | |
| — | — | — | — | — | — | — | — | — | 69.77% | 68.73% | 68.29% | 68.86% | 74.52% | — | |
| — | $2.87B | $2.73B | $2.74B | $2.7B | $2.75B | $2.49B | $2.33B | $2.33B | $2.26B | $2.19B | $2.22B | $1.64B | $1.48B | $1.56B | |
| — | $11.78B | $10.85B | $10.74B | $10.42B | $10.29B | $10.15B | $10.11B | $10.42B | $10.24B | $10.02B | $9.47B | $6.9B | $5.85B | $5.7B | |
| — | $1.77B | $1.81B | $1.69B | $1.7B | $1.73B | $1.78B | $1.76B | $1.76B | $1.82B | $1.98B | $1.93B | $733M | $349M | $331M | |
| — | $2.96B | $2.86B | $2.65B | $2.7B | $2.71B | $2.7B | $2.66B | $2.66B | $2.64B | $2.92B | $2.82B | $1.31B | $850M | $819M | |
| — | — | — | $389M | $647M | $335M | $539M | $462M | — | — | — | — | — | — | — | |
| — | $6.47B | $5.96B | $5.14B | $5.49B | $5.75B | $4.48B | $4.79B | $6.27B | $6.64B | $5.38B | $5.36B | $3.77B | $3.81B | $4.4B | |
| — | 17.78% | 17.76% | 15.89% | 17.56% | 18.15% | 14.89% | 16.57% | 20.51% | 22.17% | 18.12% | 18.59% | 18.59% | 22.42% | 26.53% | |
| — | $9.43B | $8.82B | $7.79B | $8.18B | $8.46B | $7.19B | $7.45B | $8.93B | $9.28B | $8.3B | $8.18B | $5.07B | $4.66B | $5.22B | |
| — | $715M | $729M | $719M | $636M | $553M | $925M | $1.09B | $1.44B | $1.15B | $1.09B | $1.39B | $666M | $379M | $388M | |
| — | $384M | $402M | $412M | $515M | $318M | $336M | $356M | $373M | -$505M | -$222M | -$107M | -$118M | -$181M | -$108M | |
| — | $6.14B | $5.63B | $4.84B | $5.36B | $5.52B | $3.9B | $4.06B | $5.2B | $5.68B | $4.6B | $4.34B | $3.49B | $3.71B | $4.25B | |
| — | $1.3B | $936M | $1.13B | $1.58B | $456M | $265M | -$751M | $547M | $2.58B | $578M | $798M | $811M | $640M | $784M | |
| — | $4.8B | $4.66B | $3.68B | $3.76B | $5.04B | $3.61B | $4.79B | $4.63B | $3.1B | $4.03B | $3.54B | $2.68B | $3.07B | $3.47B | |
| — | 13.2% | 13.9% | 11.36% | 12.03% | 15.9% | 11.97% | 16.56% | 15.16% | 10.36% | 13.56% | 12.27% | 13.2% | 18.02% | 20.9% | |
| — | $37M | $29M | $28M | $26M | $22M | $24M | $17M | $19M | -$9M | -$4M | $0 | $0 | — | — | |
| — | — | — | — | — | — | — | — | — | — | — | $3.54B | $2.68B | $3.07B | $3.47B | |
| — | $4.98B | $3.7B | $3.86B | $2.52B | $6.26B | $3.68B | $3.94B | $3.66B | $4.13B | $3.28B | $2.85B | $2.09B | $2.96B | $3.45B | |
| USD/shares | — | $3.75 | $3.63 | $2.77 | $2.83 | $3.75 | $2.68 | $3.57 | $3.44 | $2.29 | $2.92 | $2.51 | $2.44 | $3.06 | $3.40 |
| USD/shares | — | $3.73G | $3.61G | $2.76G | $2.82G | $3.73 | $2.66 | $3.54 | $3.41 | $2.27 | $2.89 | $2.48 | $2.41 | $3.02 | $3.37 |
| shares | — | 1.28B | 1.29B | 1.33B | 1.33B | 1.34B | 1.34B | 1.34B | 1.35B | 1.36B | 1.38B | 1.41B | 1.1B | 1B | 1.02B |
| shares | — | 1.29B | 1.29B | 1.33B | 1.33B | 1.35B | 1.35B | 1.35B | 1.36B | 1.37B | 1.39B | 1.43B | 1.11B | 1.01B | 1.03B |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative. (G): the company's own guidance — a (G) column is a guided period not yet reported; a G marker shows how the reported figure landed against the guided range. Non-GAAP-basis guidance (*) is shown as stated and never judged against GAAP actuals.
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2013–FY2026: $28.72B in buybacks, $37.12B in dividends.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
3.68×
Peer median 3.95×
EV/EBIT
20.71×
Peer median 21.68×
P/E (TTM)
24.12×
Peer median 31.96×
Peer medians compare against the 9 similar-size Medical Devices companies (of 141 listed).
Valuation over time computed as of each quarter's filing date
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Total Reportable Segments | $33,079,000,000 | $30,734,000,000 | $29,654,000,000 | $30,731,000,000 | $30,959,000,000 | — | — | — |
| Cardiovascular | $13,976,000,000 | $12,481,000,000 | $11,831,000,000 | $11,522,000,000 | $11,368,000,000 | $10,772,000,000 | $10,468,000,000 | — |
| Neuroscience Group | $10,287,000,000 | $9,846,000,000 | $9,406,000,000 | $8,959,000,000 | $8,784,000,000 | — | — | — |
| Medical Surgical | $8,815,000,000 | $8,407,000,000 | $8,417,000,000 | $7,989,000,000 | $8,469,000,000 | — | — | — |
| Other Operating Segments Including Diabetes | $3,247,000,000 | $2,892,000,000 | $2,710,000,000 | — | — | — | — | — |
| Diabetes Group | $3,112,000,000 | $2,755,000,000 | $2,488,000,000 | $2,262,000,000 | $2,338,000,000 | — | — | — |
| Other Operating Segment Misc | $135,000,000 | $137,000,000 | $221,000,000 | — | — | — | — | — |
| Cardiovascular Portfolio | — | — | — | — | — | — | — | $11,505,000,000 |
| Diabetes Operating Unit | — | — | — | $2,262,000,000 | $2,338,000,000 | $2,413,000,000 | $2,368,000,000 | $2,391,000,000 |
| Medical Surgical Portfolio | — | — | — | $8,433,000,000 | $9,141,000,000 | $8,737,000,000 | $8,352,000,000 | $8,478,000,000 |
| Neuroscience Portfolio | — | — | — | $8,959,000,000 | $8,784,000,000 | $8,195,000,000 | $7,725,000,000 | $8,183,000,000 |
| Other Segment | — | $137,000,000 | $221,000,000 | $495,000,000 | — | — | — | — |
| All Other Segments | — | $137,000,000 | $221,000,000 | $495,000,000 | $727,000,000 | — | — | — |
By Geography (USD)
| Component | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Non Us | $18,261,000,000 | $16,365,000,000 | $15,802,000,000 | — | — | — | — | — |
| Total Other Countries Excluding United States and Ireland | $18,118,000,000 | $16,250,000,000 | $15,689,000,000 | $14,756,000,000 | $15,450,000,000 | $14,491,000,000 | $13,909,000,000 | $14,272,000,000 |
| United States | $18,103,000,000 | $17,171,000,000 | $16,562,000,000 | $16,373,000,000 | $16,135,000,000 | $15,526,000,000 | $14,919,000,000 | $16,194,000,000 |
| Ireland | $143,000,000 | $116,000,000 | $113,000,000 | $98,000,000 | $101,000,000 | $100,000,000 | $85,000,000 | $91,000,000 |
| International | — | $16,365,000,000 | $15,802,000,000 | $14,854,000,000 | — | — | — | — |
| Japan Australia New Zealand Korea Canada and Western Europe | — | — | $9,979,000,000 | $9,408,000,000 | $10,126,000,000 | $9,815,000,000 | $9,287,000,000 | $9,631,000,000 |
| Middle East Africa Latin America Eastern Europeand Asia Excluding Japanand Korea | — | — | $5,823,000,000 | $5,446,000,000 | $5,426,000,000 | $4,777,000,000 | $4,707,000,000 | $4,732,000,000 |
By Product & Service (USD)
| Component | FY2021 |
|---|---|
| HVAD | $141,000,000 |
Segment Operating Income
Annual operating income by business segment, as tagged in the company's own XBRL filings. Segments need not sum to the consolidated figure — corporate costs and eliminations are typically unallocated.
By Segment (USD)
| Component | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Cardiovascular | $3,672,000,000 | $3,344,000,000 | $3,078,000,000 | $4,522,000,000 | $4,596,000,000 | $3,850,000,000 | $3,719,000,000 | — |
| Neuroscience Group | $3,062,000,000 | $3,031,000,000 | $2,822,000,000 | $3,712,000,000 | $3,858,000,000 | — | — | — |
| Medical Surgical | $2,128,000,000 | $2,071,000,000 | $2,193,000,000 | $3,048,000,000 | $3,698,000,000 | — | — | — |
| Other Operating Segments Including Diabetes | $106,000,000 | $214,000,000 | $96,000,000 | — | — | — | — | — |
| Cardiac and Vascular Group | — | — | — | — | — | — | $3,719,000,000 | $4,532,000,000 |
| Cardiovascular Portfolio | — | — | — | — | — | $3,850,000,000 | $3,719,000,000 | $4,532,000,000 |
| Diabetes Group | — | $491,000,000 | $394,000,000 | $383,000,000 | $588,000,000 | — | $546,000,000 | $739,000,000 |
| Diabetes Operating Unit | — | — | — | $378,000,000 | $583,000,000 | $598,000,000 | $546,000,000 | $739,000,000 |
| Medical Surgical Portfolio | — | — | — | $2,856,000,000 | $3,572,000,000 | $3,021,000,000 | $3,044,000,000 | $3,262,000,000 |
| Minimally Invasive Therapies Group | — | — | — | — | — | — | $3,044,000,000 | $3,262,000,000 |
| Neuroscience Portfolio | — | — | — | $3,617,000,000 | $3,765,000,000 | $3,162,000,000 | $2,915,000,000 | $3,319,000,000 |
| Other Segment | — | $49,000,000 | $10,000,000 | -$89,000,000 | — | — | — | — |
| Restorative Therapies Group | — | — | — | — | — | — | $2,915,000,000 | $3,319,000,000 |
| All Other Segments | — | — | $10,000,000 | -$89,000,000 | -$31,000,000 | — | — | — |
Operating Margin by Segment (%)
| Component | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Cardiovascular | 26.3% | 26.8% | 26% | 39.2% | 40.4% | 35.7% | 35.5% | — |
| Neuroscience Group | 29.8% | 30.8% | 30% | 41.4% | 43.9% | — | — | — |
| Medical Surgical | 24.1% | 24.6% | 26.1% | 38.2% | 43.7% | — | — | — |
| Other Operating Segments Including Diabetes | 3.3% | 7.4% | 3.5% | — | — | — | — | — |
| Diabetes Group | — | 17.8% | 15.8% | 16.9% | 25.1% | — | — | — |
| Cardiovascular Portfolio | — | — | — | — | — | — | — | 39.4% |
| Diabetes Operating Unit | — | — | — | 16.7% | 24.9% | 24.8% | 23.1% | 30.9% |
| Medical Surgical Portfolio | — | — | — | 33.9% | 39.1% | 34.6% | 36.4% | 38.5% |
| Neuroscience Portfolio | — | — | — | 40.4% | 42.9% | 38.6% | 37.7% | 40.6% |
| Other Segment | — | 35.8% | 4.5% | -18% | — | — | — | — |
| All Other Segments | — | — | 4.5% | -18% | -4.3% | — | — | — |